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4-dimensional functional profiling 
in the convulsant-treated larval 
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Julian Moger5, Andrew D. Randall2 & Charles R. Tyler1
Functional neuroimaging, using genetically-encoded Ca2+ sensors in larval zebrafish, offers a powerful 
combination of high spatiotemporal resolution and higher vertebrate relevance for quantitative 
neuropharmacological profiling. Here we use zebrafish larvae with pan-neuronal expression of 
GCaMP6s, combined with light sheet microscopy and a novel image processing pipeline, for the 4D 
profiling of chemoconvulsant action in multiple brain regions. In untreated larvae, regions associated 
with autonomic functionality, sensory processing and stress-responsiveness, consistently exhibited 
elevated spontaneous activity. The application of drugs targeting different convulsant mechanisms 
(4-Aminopyridine, Pentylenetetrazole, Pilocarpine and Strychnine) resulted in distinct spatiotemporal 
patterns of activity. These activity patterns showed some interesting parallels with what is known 
of the distribution of their respective molecular targets, but crucially also revealed system-wide 
neural circuit responses to stimulation or suppression. Drug concentration-response curves of neural 
activity were identified in a number of anatomically-defined zebrafish brain regions, and in vivo larval 
electrophysiology, also conducted in 4dpf larvae, provided additional measures of neural activity. Our 
quantification of network-wide chemoconvulsant drug activity in the whole zebrafish brain illustrates 
the power of this approach for neuropharmacological profiling in applications ranging from accelerating 
studies of drug safety and efficacy, to identifying pharmacologically-altered networks in zebrafish 
models of human neurological disorders.
Real-time cell-level imaging of neural activity is a powerful means to study the activity of neuronal assemblies at 
scales ranging from the sub-cellular to entire nervous systems. The most widely employed imaging-based read-
outs for this are fluorescent reporters of intracellular Ca2+ concentration. These effectively reflect neural activity 
as voltage changes in neurons are usually coupled closely with Ca2+ transients that arise through the gating of 
voltage-sensitive Ca2+ channels. Of the fluorophores available, GCaMPs, which can be genetically encoded, are 
amongst the most sensitive1; Ca2+ binding to the GCaMP molecule results in conformational changes that pro-
vide a fluorescent indication of increased neural activity2. GCaMPs have been employed in a range of model 
organisms3; amongst these, larval zebrafish offer an unparalleled combination of higher vertebrate (including 
human) relevance, optical transparency, and a small brain size (comprising approximately 100000 neurons)4 
allowing simultaneous spatial coverage of multiple brain regions within a fully intact connectome. Moreover, 
the availability of transgenic zebrafish, in which genetically-encoded GCaMPs are under the control of the 
pan-neuronal elavl3 promotor have greatly facilitated the potential for assessing neural network dynamics (e.g. 
refs 5–7). When coupled with imaging modalities with high spatiotemporal resolution, such as light sheet micros-
copy (LSM)8, such models offer a uniquely powerful experimental system with which to functionally characterise 
large-scale, integrated neuronal assemblies at rest4, under conditions of sensory stimulation9, 10 or, as in the case 
with the current study, following treatment with neuroactive drugs.
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Using four exemplar drugs known to induce neural network hyperactivity by different molecular mech-
anisms in both mammals and zebrafish, we utilise a combination of LSM and a transgenic zebrafish (elavl3: 
GCaMP6s)11 to quantify functional brain responses in 4 dimensions. Our approach addresses certain key chal-
lenges associated with profiling drug action in a living vertebrate, such as the contextualised quantification of 
pharmacologically-modified neural function within a 3D landscape of brain anatomy4. Accordingly, we present 
a computational image analysis framework that enables 3D anatomical registration against a standardised larval 
zebrafish brain, thus providing quantitative functional data for defined regions across the whole larval brain. 
Using this methodology we have quantified several measures of neural activity in multiple brain regions, reveal-
ing differential spatiotemporal patterns associated with differing molecular mechanisms of drug action. The use 
of in vivo extracellular local field potential recording from the optic tectum of comparable animals provides addi-
tional information on the temporal profile characteristics of drug-induced neural activity to aid interpretation of 
the GCaMP imaging data.
Here we present novel data that validate the use of this experimental system for the routine 4D functional 
profiling of drug action in the brain of a highly relevant vertebrate model. Furthermore our approach has many 
potential applications ranging from studies of CNS drug safety and efficacy, and, when combined with the relative 
simplicity of gene editing in the zebrafish, to the identification of functionally-altered network activity in various 
human neurological disorders.
Materials and Methods
Experimental animals. Transgenic elavl3:GCaMP6s, in an unpigmented Casper background, were the kind 
gift of Misha B. Ahrens (Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, Virginia, USA) 
and were used at 4 days post fertilization (dpf). This line incorporates stable cytoplasmic expression of GCaMP6s 
under the control of the elavl3 promotor11. All animal work was approved by the University of Exeter’s Animal 
Welfare and Ethical Review Body, and undertaken under project and personnel licences granted by the UK Home 
Office under the United Kingdom Animals (Scientific Procedures) Act, and in accordance with The University of 
Exeter’s ethical policies.
Test compounds. The drugs selected for study (Table 1) were: pentylenetetrazole (PTZ), a GABAA receptor 
antagonist12; pilocarpine, a muscarinic acetylcholine receptor (mAChR) agonist13; strychnine, a chemoconvulsant 
that acts predominantly via glycine receptor (GlyR) antagonism14; and 4-Aminopyridine (4AP), a K+ channel 
blocker that enhances neuronal excitability and consequently the release of various neurotransmitters including 
glutamate15, 16.
Drug Treatment and Light Sheet Microscopy. A schematic of the basic experimental process is pre-
sented in Fig. 1. Larvae were pre-exposed to each drug in a well of a 24 well plate (Table 1), and then transferred to 
another well containing drug plus the anti-nicotinic neuromuscular blocker tubocurarine (4 mM), until muscle 
tone was lost. Each drug was tested at 3 concentrations alongside an untreated control group (8 larvae per treat-
ment). The concentrations and exposure periods were selected based on our previous studies in which they were 
observed to induce convulsions, but were well below lethal concentrations in larval zebrafish17 (Supplementary 
Table 1), and also from range-finding work undertaken using wide-field fluorescence microscopy (see below). 
Following drug exposure, individuals were transferred to drug plus tubocurarine in 1.4% Low Melting Point 
(LMP) agarose, and drawn into a clear borosilicate glass capillary (940 µM internal diameter) plugged with 
1.5% LMP agarose. Control larvae were treated identically without the presence of the chemoconvulsant. Each 
mounted fish was positioned vertically (Head down), and optical sectioning was undertaken repeatedly in 
the horizontal plane from the dorsal to ventral surface of the larva. This was repeated for 6 mins generating 
200 × 10-Z-plane image stacks, each spanning a total depth of 220 μm. At the end of each 6 min run, the larva was 
checked for a normal heart rate and blood flow by microscopy to ensure viability. Standard wide-field imaging 
(see below) suggested minimal photobleaching (<10%/hour) supporting the ability to undertake longer term 
assessment. However, the image capture parameters employed were considered appropriate for obtaining a repre-
sentative period of drug-induced neural activity across all major brain structures, whilst yielding datasets suitable 
for routine image processing and analysis techniques.
The LSM (See Supplementary Figure 1) was custom built using the Open Access platform for SPIM8, 18. The 
system comprised a 488 nm Argon laser (Melles Griot, Didam, Netherlands) for illumination, a 20x/0.5 NA objec-
tive lens (Olympus, Southend-on-Sea, UK) with an intermediary magnification of 1x, followed by a 525/50 nm 
emission filter and 495 nm bandpass filter (Chroma, Olching, Germany) to collect emitted light, and a 5.5MP 
Zyla sCMOS camera (30FPS, 640 × 540 pixels, 4 × 4 binning, 40 ms exposure, Andor, Belfast, Northern Ireland) 
to capture images. The camera and rotational axis (Picard Instruments, Albion, USA) were controlled though 
μManager19 and the OpenSPIM plugin18. The Point Spread Function (PSF) of our system was determined by 
Compound CAS No.
Drug concentrations in 
external medium
Pre-imaging 
exposure period
4-Aminopyridine (4AP) 504-24-5 1, 0.5 and 0.25 mM 15 minutes
Pentylenetetrazole (PTZ) 54-95-5 5, 2.5 and 1.25 mM 20 minutes
Pilocarpine hydrochloride 54-71-7 5, 2.5 and 1.25 mM 30 minutes
Strychnine hemisulphate (STR) 60-41-3 200, 100 and 50 µM 20 minutes
Table 1. Compounds and respective exposure regimes used for imaging neural activity responses in 4dpf 
elavl3:GCaMP6s zebrafish larvae. All sourced from Sigma-Aldrich, Poole, UK.
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Figure 1. Schematic of the basic experimental process used to obtain 4D whole brain neural activity data 
from drug treated larval elavl3:GCaMP6s zebrafish (A) Larvae are cultured to 4 days post fertilisation (dpf), 
exposed to each drug, and neuromuscular blocker and embedded in agarose in a capillary tube; (B) larvae are 
then imaged on the LSM to capture the whole brain volume; (C) Resultant images are processed using a custom 
Python script in which 3D anatomical registration against a standard brain allows identification of regions of 
interest (ROIs); (D) fluorescence intensity data are summarised for ROI and automated peak analysis performed 
on the resultant temporal profiles (example plots that are automatically output are shown for illustrative 
purposes).
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performing Z-stacks of 50 × 0.5 µm fluorescent beads, embedded in 1% agarose within a glass capillary. Images 
were acquired at z-intervals of 1.5 µm using the same system settings employed during data acquisition (detailed 
above), and the PSF calculated using the MOSAICsuite PSF Tool (http://imagej.net/MOSAICsuite). The spatial 
resolution of our system was measured using a segment from a multi-grid stage micrometer (Edmund Optics, 
UK) with 100 μm divisions. The grid was imaged in the sample chamber using the same optics and medium to 
determine the pixel length of each 100 μm division. Each 100 μm division at 1 × 1 binning was 304 pixels, and at 
4 × 4 binning was 76 pixels.
Image processing and analysis. Data processing was performed using a custom Python image processing 
pipeline incorporating functions from the Scikit-image20, Scipy21 and Scikit-Learn22 libraries. Each 3D image was 
first shift-corrected using 3D registration and then down-sampled by averaging across 3 × 3 × 1 voxel blocks. 
The data were then baseline corrected by subtracting each voxel’s baseline, estimated using a sliding minimum 
filter. Due to the absence of an appropriate control with which to normalise to account for regional variations in 
the expression of elavl3:GCaMP6s, the data presented in Fig. 2 (see later) were then divided by the same base-
line. Next, a labelled reference brain (http://engertlab.fas.harvard.edu/Z-Brain/downloads.html)23 was aligned 
with each image in 3D by using key-point registration allowing full 3D affine transforms to optimise the quality 
of the alignment. Key-points comprised 14 predetermined anatomical reference points that were user-selected 
on a representative stack from each series. The optimal affine transformation for aligning the reference points 
to the expert-selected points was then determined using a standard optimisation algorithm (Umeyama). The 
whole series was then aligned to the labelled reference brain using this optimal transform, and registration was 
undertaken for 45 anatomical Regions of Interest (ROIs) selected to encompass major brain structures (see 
Supplementary Table 2). Each dataset was visually inspected for accuracy of the registration process using the 
reference brain overlay image shown in Fig. 1, panel C, and any showing poor alignment were reprocessed follow-
ing adjustment of the user defined key-points. The error of the registration process was estimated by calculating 
the median distance between the aligned reference key-points and the user selected key-points for each dataset.
For each ROI, fluorescence intensity data were provided as the time-averaged mean, median and standard 
deviation of the incorporated voxels. The median is a robust measure of the central tendency of the fluores-
cence signal within each ROI as it is less influenced by small variations in the spatial accuracy of the registration 
process. In addition, temporal profile peak analyses were undertaken for each ROI. For this, all activity profile 
Figure 2. Summary of the control fish data across 4 experiments. Data are shown as the average of ΔF/F 
( = (F1 − F0)/F0*100, where F1 = peak fluorescence intensity, and F0 = baseline fluorescence intensity) of the fish 
within each control group. Only those regions showing activity greater than the median of all areas (>0.0386) 
are labelled. Note the consistency in brain regions showing measurable baseline activity. In particular, activity 
was most pronounced in the anterior commissure, hypothalamus, tegmentum, rhombencephalon, inferior 
olive, locus coeruleus, mauthner cells, medial vestibular nucleus, superior and inferior raphe and spinal cord 
neuropil region.
www.nature.com/scientificreports/
5Scientific RepoRts | 7:  6581 | DOI:10.1038/s41598-017-06646-6
baselines underwent fine-scale smoothing using Gaussian filtering (sigma = 1.5) to preserve the signal features 
while smoothing high-frequency noise in the signal. For peak analysis, the baseline from the smoothed signal 
was subtracted (as above), and then a threshold applied of twice the standard deviation to identify significant 
peak regions. Any peaks spanning 2 or more consecutive imaging cycles (>1.875 secs, and thus considered non 
artefactual) were automatically logged and analysed, and for each animal mean peak height, peak width, peak 
separation in frames, Area Under the Curve (AUC) from summed intensities, and number of peaks were pro-
vided in an output file.
The use of an independent sample experimental design meant that the most appropriate representation of 
untreated baseline activity was the average of the median intensity values from the water-exposed animals, within 
each region. Consequently, statistical analysis of concentration-response relationships within each ROI was 
undertaken using median fluorescence intensity data comparing treated with untreated groups. This was achieved 
using Kruskal-Wallis tests coupled with Dunn’s post hoc comparisons of treated with corresponding non-treated 
control fish data. The four control groups were also compared within each ROI using the same method.
For graphical representation of relative induction or suppression of neural activity between compounds and 
brain regions, data are expressed as the % increase over the same region from the mean of the corresponding 
untreated control group according to the formula: ΔF/F = (F1 − F0)/F0*100, where F1 = treated group fluores-
cence intensity, and F0 = control group fluorescence intensity.
Wide-field fluorescence microscopy for range finding. Full details of the wide-field fluorescence 
microscopy are contained within the Supplementary Materials and Methods section. Briefly, larvae were immo-
bilized with tubocurarine, mounted in custom designed microchambers in LMP agarose, and transferred onto a 
standard inverted microscope equipped with a 10x objective, fast switching fluorescent light source and sensitive 
high speed CCD camera. Excitation was provided by constant 490 nm illumination, and images collected and 
assessed. In each case, a drug-free baseline recording of 10 mins was undertaken prior to the addition of the test 
compound to the microchamber, and subsequent recording was continued for a further 70 mins.
In vivo electrophysiology. Full details are contained in the Supplementary Materials and Methods. 
Briefly, larvae were immobilised with tubocurarine and then fixed and positioned dorsal side up in the recording 
chamber in LMP agarose containing extracellular solution (ECS). Under 4x magnification, a glass ECS-filled 
microelectrode (resistance of 3–5 MΩ) was inserted into the optic tectum (Supplementary Figure 2) to record 
extracellular local field potential from small networks of neurons. Larvae were equilibrated for 600 secs prior 
to data acquisition to establish a baseline response. Local field potential (LFP) recording protocols allowed for 
a 300secs baseline period before drug addition to the ECS and experimental recording lasted for a total of 4200 
secs. During all experimentation on larval zebrafish, the heart rate was monitored visually to confirm viability. 
Comparisons of the frequency (Hz) and power (mV2) of neuronal network events were made before (0–900 secs) 
and after drug addition (3300–4200 secs). Student’s t-tests were performed on paired data with statistical signif-
icance defined as P < 0.05.
Results
Estimates of registration error, and spatial and temporal resolution. The average of the median 
error of the automated 3D affine registration processes was calculated as 27.56 ± 0.43 μm (median, ± SEM, 
n = 128 datasets), a figure in line with the error reported for an alternative registration process published by 
Ahrens et al.24.
The spatial resolution of the system is summarised in Supplementary Figure 3. The theoretical point spread 
function (PSF), calculated from the average of 50 × 0.5 μm fluorescent beads and expressed as the width at half 
maximum intensity, was 0.751 μm. The measured lateral resolution was 3.04 pixels per μm, or 0.76 pixels per μm 
when employing the 4 × 4 binning used to achieve faster acquisition rates for registration of broad brain regions.
The temporal resolution of our system was 1.875 secs for each full z-series (including stage movement and 
image acquisition). This cycle time was suitable for capturing dynamic neural events at a level of spatial resolution 
appropriate for our intended aim of mapping whole brain functional responses to neuroactive drug treatment.
Mapping whole brain neural activity in untreated larvae. Control larvae exhibited a relatively low 
level of neural activity compared with drug-treated animals; however, there was consistent above-baseline activity 
in certain brain regions (Fig. 2). Active regions were mainly rhombencephalic in origin and included the area 
postrema (sensory circumventricular organ involved in multiple autonomic processes)25, inferior olive (predom-
inantly associated with adaptive motor control)24, locus coeruleus (involved in autonomic arousal associated 
with stress)26, 27, Mauthner cells (control of the escape response)28, raphe (serotonergic nuclei with functions in 
nociception, sleep-wake cycles and alertness)29, and medial vestibular nucleus (vestibular signal processing)30, 
in addition to the telencephalic anterior commissure (interhemispheric functional connectivity)31, diencephalic 
caudal hypothalamus (multisystem homeostasis)32, and mesencephalic tegmentum (motor control)33, 34.
Mapping whole brain neural activity during drug treatment - time averaged intensity 
data. Treatment with the 4 drugs confirmed distinct spatiotemporal patterns of neural activity initially iden-
tified using standard wide field fluorescence imaging (Supplementary Figure 4). Using LSM, this differential 
patterning was evident both in the anatomical ROIs being activated or supressed, as well as in the temporal profile 
characteristics exhibited. Figure 3 exemplifies the different patterns of neural activity shown for each drug, com-
pared with that exhibited by a typical untreated control animal. From the temporal profiles shown, one can see 
the pronounced, relatively high amplitude Ca2+ transients in the drug-treated larvae compared with the low level 
undulation of the untreated state. Furthermore, the waveform, peak separation, peak height and number of peaks 
www.nature.com/scientificreports/
6Scientific RepoRts | 7:  6581 | DOI:10.1038/s41598-017-06646-6
clearly varies between drugs, in addition to the regions affected, as shown in the pseudo-coloured fluorescence 
intensity images that accompany these profiles.
For each drug, Fig. 4 summarises the median GCaMP6s fluorescence intensity for each ROI as a % increase 
compared with the corresponding control group value, thus allowing visual comparison of the relative induc-
tion or suppression of each ROI compared to each another, and between drugs. 4AP-treated animals exhibited 
a widespread and considerable increase in activity across the majority of ROIs. None of these exhibited a reduc-
tion in activity and a number (e.g. pallium, habenulae, various tectal sub-regions, and the torus longitudinalis 
and semicircularis) exhibited average levels of more than 7 times that shown in the same ROI from the mean 
of the untreated control larvae. Although some of these areas also showed considerable inter-animal variation, 
Figure 3. Example larvae exposed to each of the 4 neuroactive drugs plus an untreated control. Images are 
median intensity projections across time, for each z-plane (0–9 ventral to dorsal surface) and the corresponding 
temporal profile with each line representing the median intensity of the voxels within each of the 45 
3D-registered anatomical regions. Each panel represents an example larva treated with: (A) PTZ, (B) 4-AP, (C) 
Pilocarpine (D) Strychnine and (E) untreated control. Superimposed on each image are outlines of the regions 
registered within that z-plane. From each montage, one can clearly see differences in the GCaMP fluorescence 
intensity within specific brain regions, and the different characteristics of the temporal profiles generated within 
these regions of interest. Accompanying colour scales show the fluorescence intensity range for each montage as 
the median fluorescence intensity value averaged over the experimental duration.
www.nature.com/scientificreports/
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Figure 4. Summary of the voxel GCaMP6s fluorescence intensity obtained per anatomical region for each of 
the model chemoconvulsant compounds applied. Data are expressed as the time-averaged median fluorescence 
intensity values, averaged across all fish in that treatment group, expressed the % change versus the corresponding 
control fish group (second left column presented for brevity as the mean across the 4 control groups): 
ΔF/F = (F1 − F0)/F0*100 (where F1 = treated group fluorescence intensity, F0 = control group fluorescence 
intensity). Colour coding represents the degree of activation (shades of red), or suppression (shades of blue) versus 
that region in the control larvae, relative to other brain regions within that treatment group. The treatment group 
shown is that at which the highest activity was observed, which was the top concentration for 4AP, pilocarpine 
and strychnine, but 2.5 mM (the second highest) for PTZ due to a slight dip in neural activity at the highest 
treatment level. Colour coding in the left most column represents anatomical categorisation as subdivisions of 
the telencephalon, diencephalon, mesencephalon and rhombencephalon, along with ganglia (green) respectively 
from top to bottom. n/a – values not obtained due to a failure in registration probably due to the high z-depth of 
this region. N = 8 larvae were imaged per group. For corresponding SEM values, see Supplementary Table 3.
www.nature.com/scientificreports/
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(Supplementary Table 3) several ROIs showed a significant and concentration-dependent increase in median 
fluorescence intensity (Supplementary Table 4), namely the torus semicircularis, Mauthner cells, and the medial 
and tangential vestibular nuclei (all P < 0.05).
Larvae treated with PTZ showed less widespread and extensive activation compared with the 4AP treated 
larvae, but with specific ROIs exhibiting a range of increased and decreased % activity compared with the corre-
sponding control animals (Fig. 4). Most notably, there was a greater than 15% reduction in GCaMP fluorescence 
in the eminentia thalami, inferior olive, lateral reticular nucleus, and the spinal cord and associated neuropil 
region. Again, inter-animal variability in some cases was high (Supplementary Table 3), and consequently only 
the eminentia thalami, preoptic area and spinal cord exhibited a significant reduction in activity compared with 
the corresponding untreated larval data (all P < 0.01). This variability was most evident in terms of the areas 
showing apparent stimulation of activity of activation as a number of ROIS exhibited a >50% increase in activity 
compared with control larvae (e.g. pallium and subpallium, habenulae, pretectum, lobus caudalis cerebelli, and 
valvula cerebelli), although only one achieved statistical significance (Olfactory bulb, P < 0.01, Supplementary 
Table 4).
When the time averaged GCaMP fluorescence intensity data were considered, pilocarpine treatment resulted 
in predominantly suppressed neural activity compared with control larvae (Fig. 4). Most notably, >30% reduc-
tions in fluorescence intensity compared with the corresponding control data were observed in the anterior 
commissure, rostral hypothalamus, area postrema, lobus caudalis cerebelli, and the noradrendergic neurons of 
the interfascicular and vagal areas. As occurred with the other drugs, there was some inter-animal variability 
(Supplementary Table 3) and consequently only the area postrema (P < 0.05), and the noradrendergic neurons of 
the interfascicular and vagal areas (P < 0.01) were significantly lower than in controls, in addition to the inferior 
raphe (P < 0.05) and spinal cord (P < 0.01, Supplementary Table 4). Conspicuous by their increased levels of 
activity (>18% of controls) were the pallium, subpallium, habenulae, and interpenduncular nucleus, although 
none achieved statistical significance (Supplementary Table 4).
In strychnine-exposed larvae, there was an apparent altered activity in multiple ROIs compared with the 
untreated control larvae (Fig. 4), most notably >100% increase over controls in multiple sub-regions of the dien-
cephalon (e.g. the dorsal and ventral thalamus, posterior tuberculum, and pretectum), and >30% decrease in 
activity in the olfactory bulb and rostral hypothalamus. Despite the widespread trends for altered GCaMP fluores-
cence in many brain regions, however, there were no statistically-significant changes in any ROI (Supplementary 
Table 4) perhaps, again, due to high inter-individual variability (Supplementary Table 3).
Collectively, from these data it was clear that averaging fluorescence intensity across the whole experimen-
tal period resulted in the loss of resolution and statistical power, with respect to relative regional changes in 
neural activation or suppression following drug treatment. Consequently, the detailed analysis of resultant 
waveforms within each region was required in order to reveal the more subtle effects of treatment with these 4 
pharmacologically-distinct chemoconvulsant drugs.
Mapping whole brain neural activity during drug treatment - temporal profile waveform 
analysis. A summary of the data obtained from the temporal waveform profile analysis is provided within 
Supplementary Figure 5, and graphically presented in Fig. 5.
Compared with untreated larvae, those exposed to 4AP exhibited an overall trend for highly increased AUC, 
peak heights (Fig. 5, note this is divided by 10 to allow plotting on the same scale) and peak width. Corresponding 
with this was a widespread reduction in peak number and increased separation suggesting that 4AP-exposed ani-
mals showed larger and more intense (area, duration and intensity), but less frequent, bursts of neural activity in 
multiple brain regions compared with those in control animals. These trends were further supported by a number 
of statistically-significant, concentration-related changes within specific brain regions (Supplementary Table 5). 
Significant concentration-related increases in AUC and peak height were observed most consistently in mesen-
cephalic and rhombencephalic regions, and were especially centred on tectal, cerebellar and vestibular centres 
as well as within the vagal ganglia (example concentration response curves shown in Fig. 6). Similar significant 
changes were observed with respect to peak width and number further supporting the induction of fewer, larger 
spikes of activity occurring in a concentration-dependent manner (although no significant effects in peak sepa-
ration were detected in any brain region assessed, see Supplementary Table 5).
Larvae exposed to PTZ (Fig. 5) generally exhibited increases in AUC and peak height, together with an 
increase in peak separation and decreased peak number (note peak activity was at 2.5 mM rather than 5 mM). This 
again suggests less frequent bursts of higher intensity activity in particular regions compared with untreated lar-
vae. The areas exhibiting the most consistently significant elevations in peak intensity and AUC (Supplementary 
Table 5) were centred on the rhombencephalon, particularly in sub-regions of the cerebellum, in addition to some 
regions of the mesencephalon (example concentration-response curves shown in Fig. 6). However, few significant 
changes in peak width were observed. Conspicuously, only 2 regions exhibited significant reductions in activity 
(the preoptic area and the emenentia thalami), both of which were in the diencephalon (Fig. 6 and Supplementary 
Table 5). As stated, increased intensity was mirrored with significant reductions in peak number and increased 
peak separation across many of the same areas (Supplementary Table 5).
Following exposure to pilocarpine, larvae generally exhibited decreased peak height and AUC, along with 
decreased peak number and increased separation, but with a concomitant increase in peak width (Fig. 5). This 
overall pattern suggested a reduction in event intensity, magnitude and frequency in pilocarpine-treated larvae, 
alongside a slight increase in event duration. These changes were observed predominantly in the rhombenceph-
alon, but also in the tegmentum, spinal cord neuropil region and the anterior commissure. These trends were 
supported by statistically-significant responses in a number of defined brain regions (Supplementary Table 5 with 
example curves in Fig. 6). In most cases, however, these effects were significant only at the lower or intermediate 
treatment concentrations.
www.nature.com/scientificreports/
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Figure 5. Results of the profile peak analysis. (A) Maximum intensity projection through a larva with overlays 
showing the positions of the 45 registered anatomical regions. (B) The various peak analysis parameters 
automatically quantified for each registered anatomical region, within each fish, are defined in panel B. For 
illustrative purposes only partial example profiles for a PTZ-exposed (red) and control fish (blue) are shown 
and the various parameters highlighted on these traces. (C) Peak profile analysis data for each region across 
treatments. The treatment group shown is that at which the highest activity was observed (Top concentrations 
for 4AP, pilocarpine and strychnine, and 2.5 mM for PTZ due to a slight dip in neural activity at the highest 
treatment level) Each data point is the mean across all fish/treatment group expressed as the % change versus 
the mean of the corresponding control group (F1 − F0)/F0*100, where F1 = treated group value, and F0 = control 
group value. Note that for the AUC and the peak height profiles, 4AP data were divided by 10 to allow plotting 
on the same axis. Data also summarised in Supplementary Figure 5.
www.nature.com/scientificreports/
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Larvae exposed to strychnine exhibited a general trend for elevated AUC and peak height (Fig. 5 and 
Supplementary Figure 5), however, none of the ROIs exhibited a statistically-significant change in activity when 
compared with the corresponding untreated control larva data (Supplementary Table 5). In addition, there was 
a concomitant trend for reduced peak number and increased separation and variable changes in peak width in 
strychnine-treated animals. A number of ROIs exhibited a significant concentration-related decrease in event 
number and increase in separation (Supplementary Table 5) compared with untreated larvae. Many of the 
concentration-related changes in peak number and separation were confined to sub-regions of the rhomben-
cephalon and spinal cord whereas areas showing a significant reduction in peak width were conspicuous by the 
dominance of the mesencephalon (example curves shown in Fig. 6).
In vivo electrophysiology. A summary of the data obtained from electrophysiological recordings in 
drug-treated 4dpf elavl3:GCaMP6s larvae are presented in Fig. 7, with full results contained within Supplementary 
Figures 6–10. Following application of 1 mM 4AP, the frequency of neuronal network activity was significantly 
increased (P < 0.05), however there was no significant effect on power. Interestingly, the significant increase in 
tectal region AUCs observed in our functional imaging may reflect this elevated spiking across large neuronal 
populations resulting in large scale GCaMP fluorescence increases, with little time for recovery in between. 
Exposure to 5 mM PTZ resulted in reduced event frequency (P < 0.05) with no effect on power. The former 
mirrored the observed reduction in tectal fluorescence intensity, peak number and frequency detailed above. In 
contrast, pilocarpine exposure (1 mM) resulted in an increase in event power (P < 0.05), but not in frequency, 
and exposure to 200 μM strychnine resulted in no significant changes in either parameter. The imaging data for 
pilocarpine suggested relatively widespread reduction in activity, however this was predominantly observed in the 
rhombencephalon. Similarly, the absence of any effect of strychnine exposure perhaps reflects the relatively low 
occurrence of GlyR in mid- and forebrain regions (see Discussion), and both of these points illustrate the issue 
of relatively low spatial coverage when using electrophysiological recording approaches to gather information on 
the large-scale modulation of neural networks.
Figure 6. Example concentration response curves generated for selected brain regions of interest in fish 
exposed to each of the 4 drugs. To provide representative curves, all data shown are those derived from 
measurements of mean peak fluorescence intensity across all larvae within that treatment group, except 
pilocarpine noradrendergic (NA) neurons of the interfascicular and vagal areas for which the AUC is presented 
(divided by 10 to allow plotting on the same axis) and all of the strychnine data (peak separation data shown). 
Data are shown as the average of the median fluorescence intensity measures obtained for each fish in that 
treatment group, ±SEM (n = 7–8). All statistical analyses were undertaken using a Kruskal Wallis analysis 
across treatment groups, followed by a Dunn’s post-hoc test in which each drug-treated group was compared 
with the corresponding control group. *Denotes significance at the p < 0.05, and ** at the P < 0.01 level in order 
of lines on graph. Strychnine significance levels are shown below each point in order of the legend. For full 
concentration-response datasets please see Supplementary Table 5.
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Figure 7. Summary of the electrophysiology data obtained after exposure to the 4 drugs. Panel (A) 
Experimental trace and supporting spectrogram of basal waveform activity recorded from the optic tectum 
of untreated control zebrafish larvae. (B) The baseline normalised frequency and power of neuronal network 
events in untreated control larvae does not change over the time course of the experiment (n = 6 zebrafish). (C) 
Representative traces obtained from larvae exposed to the 4 exemplar neuroactive drugs and below each trace, 
graphs showing control versus treated fish neural event frequency and power. In each case, data are shown as 
the Mean ± SEM (n = 3 larvae, except pilocarpine = 2). Baseline and post-treatment traces were compared using 
paired Student’s t-test from which * denotes a significant difference at the P < 0.05 level.
www.nature.com/scientificreports/
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Discussion
The power of transgenic zebrafish and LSM for functional 4D drug profiling in the vertebrate brain. 
Here we show that the combined use of a pan-neuronal, genetically-encoded Ca2+ sensor in transparent larval 
zebrafish with LSM affords an extremely powerful approach for the quantitative functional analysis of vertebrate 
neural networks, following drug treatment.
A key limiting factor in interpreting LSM-generated neural function data has been the efficient transformation 
and 3D anatomical registration of the many resultant images. This has posed a significant challenge for accurately 
identifying ROIs and associated activity profiles when quantifying treatment-related effects4. We have overcome 
this by developing and applying a novel Python image processing pipeline in which we are able to automatically 
superimpose captured image voxel data onto a standardised 3D anatomical map of the larval zebrafish brain23 
and extract spatiotemporal profile data for each registered brain region. Our methodology allows us to quantify 
treatment-related changes in neural function within and between specific ROIs, and to compare neuropharmaco-
logical profiles between different treatment regimes. We have demonstrated, using selection of chemoconvulsant 
drugs, that this type of approach is suitable for the identification and quantification of activity across large-scale, 
integrated neuronal assemblies, and greatly expedites the time and region-directed analysis of network activation 
after drug treatment.
Control animal activity is associated with arousal, alertness, and escape responsiveness. In 
untreated control larvae, there was a high degree of consistency in brain regions showing low level elevation of 
GCaMP fluorescence, compared with the corresponding baseline intensity. Most of these regions were within the 
rhombencephalon, most prominently the inferior olive, locus coeruleus, Mauthner cells, raphe and medial vestib-
ular nucleus. Consistent with the nature of our conscious, but immobilised, preparation, these regions are notable 
for their functional roles in sensory processing, arousal, and the escape response24, 26–30, 35. Some this of this low 
level activity observed could indeed reflect network-wide responses to accelerational, photic and or auditory 
stimulation that may be present due to movement of the stage and/or laser illumination during imaging. Further 
supporting this, the tegmentum was the only mesencephalic region showing consistently high activity in control 
larvae, having a key role in the coordination of sensory inputs and motor control33, 34, and particularly high activ-
ity was also noted in the anterior commissure in the telencephalon, and the caudal hypothalamus in the dienceph-
alon which are involved in functional connectivity31 and autonomic process control32 respectively. The inferior 
olive, which is thought to be essential for adaptive motor control24, also showed consistent above-baseline levels 
of spontaneous neural activity in control animals. Interestingly, a number of previous authors9, 10, 36 have reported 
the existence of a ‘hindbrain oscillator’ adjacent to the inferior olive that exhibited ‘slow lateralized oscillations’ 
in larvae in the absence of any exogenous sensory stimulation. In support, the coefficient of variation of peak fre-
quency in the inferior olive, across all control larvae, was 33% (n = 32), suggesting a relatively consistent temporal 
activity profile in this region. Furthermore, the mean frequency, in seconds (38, n = 32) is broadly in line with 
the oscillatory period of 20–30 s reported by Ahrens et al.9. Collectively these data support the suitability of our 
approach with respect to the identification and quantification of neural signals within discrete brain structures.
Different pharmacological mechanisms elicit distinct spatiotemporal neural activity patterns. 
Exposure to the K+ channel blocker 4AP resulted in considerable and widespread GCaMP activation, particularly 
in tectal and cerebellar nuclei. Very little is documented regarding the distribution of Kv1 channels and associated 
neural circuitry, or the activity of K+-blockers in the zebrafish CNS, however, Fosque et al.37 recently published 
a confocal image of CNS activity following exposure to 800 μM 4AP, from transgenic zebrafish larvae expressing 
the novel photoconvertible Ca2+ sensor CaMPARI. CaMPARI expression was evident throughout the brain and 
in particular the hindbrain and spinal cord following 4AP treatment, although, due to the nature of the CaMPARI 
reporter, the temporal profile and regional quantification of activity were not available for close comparison with 
our data. In rats injected with 4AP or picrotoxin (a PTZ-like GABAA antagonist), Salami et al.38 reported distinct 
EEG patterns: GABAA antagonism resulted in rapid focal onset and dissipation, whereas 4AP administration 
resulted in more diffuse activity. Furthermore, it was noted that high frequency oscillations differed between 
4AP and picrotoxin: fast ripples were characteristic of picrotoxin exposure (thought to reflect hypersynchronous 
firing of principle glutamatergic neurons); and slow ripples characteristic of 4AP exposure. These descriptions 
resonate with the evolution of network hyperactivity seen here (see also Supplementary Videos 2 and 4), in which 
4AP treatment resulted in a relatively slow progression of GCaMP activation across the entire brain, whereas 
PTZ treatment resulted in sharp rhythmic spiking within discrete brain regions from the onset. Distinct in vivo 
electrophysiological profiles were also obtained following 4AP and PTZ treatment: PTZ-induced network activity 
was regular, consistent and discrete, whereas 4AP-induced network activity was more frequent and variable in 
terms of magnitude. When considering these profiles alongside the functional imaging output, in most cases, the 
4AP imaging data revealed a small number of large magnitude increases in GCaMP fluorescence across multiple 
brain regions (see also Supplementary Video 2) perhaps suggesting that the temporal resolution of the imaging 
was insufficient to capture the faster temporal components seen with in vivo electrophysiology; rather it mani-
fested as a single global elevation in GCaMP fluorescence. This possibility highlights the relative advantages and 
disadvantages of each approach, namely the superior spatial resolution juxtaposed with inferior temporal resolu-
tion of the functional imaging versus in vivo electrophysiology. It is also important to reiterate that, although both 
methods report neural activity, electrical recordings and GCaMP-based imaging do not measure identical phe-
nomena. Pivotally, extracellular electrical recording can effectively report sub-threshold electrical activities, for 
example those arising from synaptic activity, and in particular synchronised synaptic activity; whereas GCaMP 
signals will predominantly arise from suprathreshold membrane potential changes and the voltage-gated Ca2+ 
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entry they drive. Also the influence of the kinetics of Ca2+ binding and particularly unbinding to/from GCaMP 
determine the nature of how it can report neural activity.
GABA-immunoreactive cells are found in the CNS of zebrafish early in development, and by 3dpf their distri-
bution is similar to that of comparatively developed mammals39, 40. The reported distribution shows some similar-
ities with our temporal analysis-derived peak height and AUC data, which suggest removal of inhibitory synaptic 
drive triggering neural hyperactivity in a number of prominent regions. In support, Mueller et al.40 reported many 
GABA-immunoreactive (-IR) cells in the olfactory bulb and subpallium, with some penetration of the pallium; all 
regions showing elevated GCaMP activity here following PTZ-treatment. These authors also reported GABA-IR 
cells across the diencephalon, but noted relative absences in the anterior preoptic area and emenetia thalami, 
both areas of which showed conspicuous reductions in peak GCaMP fluorescence after PTZ treatment. These 
authors also reported detailed thalamic expression of GABA-IR: higher levels were observed in posterior parts of 
the dorsal and ventral thalamus into the prectectum (which is the only one of these regions showing a significant 
increase in peak height in our data), compared with a relative absence in the anterior portions of these regions. 
Although we are able to provide region-specific fluorescence intensity measures, our registration method does 
not differentiate between posterior and anterior sections of such regions. At present we can only quantify median 
intensity across the whole region which may mask sub-regional variations in expression revealed using GABA-IR. 
Rhombencephalic regions reported as having notable GABA-IR cell populations by Mueller et al.40 centred on 
the cerebellum and sub regions, such as the valvula and corpus cerebelli. Our data also showed elevated GCaMP 
fluorescence in these regions which was consistently higher than control levels, with respect to both peak height 
and AUC from the temporal profile peak analysis. A key consideration to bear in mind when comparing the out-
put from our functional imaging approach, versus descriptions of the distribution of neurotransmitters or their 
target receptors, is that our approach provides quantitative data on whole network activation and suppression. 
For example, each neural target possesses a network of stimulatory or inhibitory inter-neuronal connections 
with other regions, which may be functionally activated regardless of the presence or absence of target recep-
tors. Similarly each of these has multiple downstream regional activation profiles, which may be targeted by the 
neural circuit under investigation, as well as other circuits and inputs independent of the initial target network. 
Consequently, the presence or absence of immunoreactivity in a specific region is not necessarily a predictor of 
activation after pharmacological treatment. As such our method’s key strength is in providing a greater under-
standing of network structure and regional cross-talk than is achievable using non-functional imaging-based 
approaches. This allows us to understand which neural circuits are affected by drug treatment, rather than which 
act as the initiator or initial propagator of such activity.
No comparable zebrafish functional imaging data are available. However, Van Camp et al.41 employed func-
tional Magnetic Resonance Imaging (MRI) in rats dosed with PTZ and reported enhanced activity in cortical 
regions, the hypothalamus and brain stem. They also identified that the neocortex (analogous to the dorsal pal-
lium in zebrafish) was strongly involved in PTZ-induced hyperactivation. Although we observed some enhanced 
activity in the telencephalon, there was a relative absence of significant-concentration-related effects on measures 
of GCaMP fluorescence intensity. One exception was the olfactory bulbs, which exhibited a highly significant 
elevation in peak height, but only at the lowest PTZ concentration. It could be postulated that this reflects an 
initial olfactory area response, subsequently superseded by global network hyperactivity at higher PTZ concen-
trations. As stated, Van Camp et al.41 also reported elevated MRI signals in the hypothalamus, thalamic regions 
and ‘brain stem’ although the specific regions were not revealed. Here, (hypo)thalamic regions by and large 
exhibited modest, non-significant changes, but a number of mid- and hindbrain structures showed significant 
concentration-related increases in GCaMP fluorescence after exposure to PTZ, particularly focussed on the tec-
tum and cerebellum.
Pilocarpine exposure typically resulted in a trend for reduced GCaMP fluorescence, particularly in the rhomb-
encephalon. No comparable zebrafish functional imaging data are available and data on the occurrence and dis-
tribution of mAChRs in zebrafish are limited. Park et al.42, however, showed that the mixed mAChR/nicotinic 
receptor agonist carbachol reversibly suppressed electrically-evoked field potentials in the isolated telencepha-
lon of adult zebrafish in a dose-dependent manner. These authors noted that, in the rat telencephalon, mAChR 
activation has opposing effects due to its inhibition of K+ conductance resulting in neuronal excitation, and 
simultaneous activation of GABAergic inhibition resulting in neuronal depression. Furthermore, this effect is 
carbachol-concentration dependent in rats, with enhancement of evoked activity predominant at low concentra-
tions and the opposite true at higher concentrations. It is possible, therefore, that our observations of reductions 
in GCaMP fluorescence across multiple regions reflect inhibitory dominance due to the relatively high concen-
trations of pilocarpine used. In contrast with the predominant inhibition of GCaMP fluorescence across mesen-
cephalic and rhombencephalic regions, some forebrain regions exhibited a trend for modest (non-significant) 
elevations in GCaMP fluorescence. Interestingly, the in vivo electrophysiology exhibited a significant increase in 
event power in the optic tectum following pilocarpine treatment. Although perhaps surprising given the modest 
elevation in GCaMP activity observed in the forebrain, as discussed previously, the two methods do not provide 
identical readouts. In addition, electrophysiological recordings sample small sub-populations of cells within the 
wider region, whilst GCaMP fluorescence data reflect the median intensity value for that whole region within 
which isolated populations of cells may show much higher localised activity in response to drug treatment (for 
example as observed in the subpallium). This further highlights the difficulty in interpreting electrophysiological 
data, with its low spatial resolution and coverage, in the context of whole, or even regional, brain functionality.
Strychnine exposure resulted in a general trend for elevated time-averaged GCaMP activity. However, despite 
the apparent widespread activation across multiple regions, the responses exhibited between animals were var-
iable, and no significant effects on peak height or AUC were observed. Assessment of the significant effects 
of strychnine treatment on other peak parameters revealed that, in the vast majority of cases, these were con-
fined to the hindbrain and spinal cord. This pattern is consistent with the role of glycine as the major inhibitory 
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neurotransmitter of the caudal CNS, reflected in the distribution of the GlyR which shows a clear rostral to caudal 
increase in expression in both mammals43 and zebrafish44, 45. Despite this, however, there were still no significant 
increases in GCaMP activity (median intensity, AUC or peak height) within hindbrain and spinal cord regions, 
perhaps due to the relatively high variability in responsiveness shown between individual animals. A lack of a sig-
nificant effect, on either event power or frequency, was also evident from the in vivo electrophysiology following 
strychnine treatment. This however, is more easily explained due to the likely low density of GlyR in the optic 
tectum of these animals, and the predominant role of glycine in hindbrain and spinal cord neurotransmission. 
Interestingly, Malosio et al.46 observed that rat GlyR expression was abundant amongst cell populations known 
also to express GABAA receptors, and speculated that coexpression may allow more precise control of inhibitory 
inputs. Our findings may also support this at a functional network level. When considering the time-averaged 
median intensity data, the spatial distribution of regions showing altered neural activity after exposure to both 
PTZ and strychnine were broadly similar, but with the generally lower activity evident in strychnine-exposed 
larvae perhaps reflecting the lower density of GlyR compared with GABAA receptors in midbrain structures.
Two regions that were consistently (significantly) affected across all drug-treated groups were the Mauthner 
cells and the medial vestibular nucleus. Mauthner cells in the Goldfish have been shown to be sensitive to the 
effects of strychnine, the GABAA antagonist bicuculline, as well as the voltage-gated potassium channel blocker 
dendrotoxin I47. This is of interest as exposure here, to representatives of both of these pharmacological classes, 
resulted in evidence of elevated GCaMP fluorescence and thus neural activity in the same discrete region. The 
fact that both the Mauthner cells and vestibular nuclei appear to be consistently affected (either positively or neg-
atively) is perhaps unsurprising given the nature of our conscious larval preparation, and that multiple auditory 
and vestibular afferents are known to innervate Mauthner cells in larval zebrafish48.
The future of functional neuropharmacological profiling in zebrafish. Despite the small scale of 
the zebrafish brain, there is still currently a trade-off between spatial and temporal resolution for applications 
focussed on whole brain functional profiling49. Our approach was appropriate for the capture of neural activity 
within specific brain regions following treatment with our selected drugs, however, faster acquisition rates would 
allow greater temporal resolution as well as higher spatial resolution at any given acquisition rate. In this respect, 
the use of piezoelectric drives to move illumination and detection objectives relative to a static sample holder 
to minimise accelerational forces, in combination with a faster camera, would allow more rapid cycle times. 
Another consideration is the differential expression of GCaMP across different anatomical regions. Arrenberg 
and Driever4 pointed out that the HuC/elavl3 promoter induces relatively low levels of expression in the dienceph-
alon at 5dpf, and that GCaMP expression is cytosolic rather than nuclear. Although the use of untreated versus 
treated groups, and baseline-corrected control animal data allowed comparison of relative activity levels within 
regions here, diencephalic regions do appear underrepresented in terms of significant concentration-related 
effects, especially when assessing the peak analysis data. Analysis of the % fluorescence intensity (% of the average 
across the whole brain) exhibited by each broad brain region compared with the overall average for all regions, 
reveals that the diencephalon, mesencephalon and rhombencephalon exhibit 75%, 111% and 127% of the whole 
brain mean fluorescence respectively, whereas the telencephalon and ganglia exhibit just 39% and 52% respec-
tively (Supplementary Table 6). It is not possible to say whether these regional differences reflect low inherent 
expression or low activity. The occurrence of significantly elevated activity within specific structures from all of 
these broad regions following drug treatment, however, suggests that any differential expression did not ham-
per our ability to detect the effects of the drugs that were applied. Nevertheless, such approaches would benefit 
greatly from the identification of other promotors4, particularly those allowing fluorophore-based differentiation 
between brain regions. The cytosolic expression of GCaMP6s also has the potential to confound precise cellular 
location of neural activity4. For our neuropharmacological profiling approach, which focusses on broad scale 
expression patterns and the analysis of dynamic neural network activation and suppression, this factor is less 
important. However, single cell, and even subcellular resolution is clearly achievable using multi-photon based 
systems (see Supplementary Figure 11 and Video 5), and therefore for experimental paradigms that require cellu-
lar detailed assessment, nuclear and other compartmentalised sensors would be desirable.
In summary we have demonstrated the power of using a pan-neuronal genetically-encoded Ca2+ sensor in 
transparent larval zebrafish, along with LSM, for profiling integrated system-wide neural circuit responses to 
treatment with CNS-active drugs in a highly relevant vertebrate model. Our approach has clear potential for 
application to many areas of CNS-focussed research, particularly when combined with emerging technologies 
that have greatly simplified in vivo gene editing in the zebrafish50. In the current context of compounds resulting 
in neural network hyperexcitability, this includes: the identification of convulsive properties and their respective 
mechanisms as side effects of new drugs, by allowing comparison of resultant neural activity patterns against a 
library of known pharmacology-linked phenotypes; for testing the efficacy and identifying novel mechanisms of 
action of anticonvulsive drugs; and for aiding in the clarification of poorly understood molecular mechanisms. 
More generally this approach has considerable potential in research encompassing the assessment of spatiotem-
poral neural network functionality in the normal and diseased vertebrate brain.
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